STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Sutro Biopharma has a 1 year low of $1.70 and a 1 year high of $6.13. The business has a fifty day moving average of $2.98 and a 200-day moving average of $3.50.